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Fig 2. Acne fulminans. Complete resolution of the
inflammatory lesions with residual scarring after treatment
with cyclosporine and isotretinoin.
Fig 1. Acne fulminans. Initial presentation with draining
pustules and crusted papules and nodules on the back.
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Letters e39the lesions improved, and 4 months later, cyclo-
sporinewas discontinued. A total dose of isotretinoin
100 mg/kg could be completed, and he presented an
almost complete resolution of the inflammatory
lesions with some residual scarring (Fig 2). No
significant side effects or laboratory abnormalities
were observed during treatment.
AF is a rare condition that is considered the most
severe form of acne. It is characterized by a sudden
onset of ulcerative, crusty, painful lesions. Most
patients are young teenagers with previous mild to
moderate acne. It is considered a severe inflamma-
tory diseasewith abscess formation and hemorrhagic
crusts accompanied by high temperature, asthenia,
anorexia, and often asymmetric polyarthralgias.1
In this case, laboratory findings showed an
intense neutrophilic leucocytosis and elevation of
erythrocyte sedimentation rate and C-reactive
protein. The etiology of AF is appears to be
multifactorial.2 The diagnosis is usually clinical. The
differential diagnosis includes other disorders such
as PAPA3 syndrome and SAPHO syndrome.4Open access under CC BY-NC-ND license.Oral antibiotics are usually ineffective. The
combination of oral isotretinoin and systemic
corticosteroids is the treatment of choice,1 but
recurrences are not unusual when steroid dose is
tapered. We have found only 1 report describing a
good response of AF to a combination of cyclo-
sporine and prednisolone.5 To our knowledge this is
the first report showing a good response to
cyclosporine combined with isotretinoin. Because
this regimen has a very good short-term safety
profile (particularly in young persons), it can be an
alternative in patients with AF when systemic
steroids are either ineffective or contraindicated.
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Complete pathologic response after
neoadjuvant treatment with vemurafenib for
malignant melanoma
To the Editor: Invasive melanoma on the left arm was
diagnosed in a 32-year-old male patient. The initial
diagnosis wasmade by skin biopsy, which revealed a
nonulcerated melanoma of 3 mm depth. The patient
underwent reexcision and sentinel lymph node
Fig 2. Site of prior melanoma, shown in Fig 1, after 8
weeks of treatment with vemurafenib.
Fig 1. Melanoma before neoadjuvant vemurafenib treat-
ment. Tru-Cut biopsy from the recurrent skin lesion was
positive for melanoma and left an open wound at the site,
which required prolonged hospitalization.
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melanoma. Two months later, the patient presented
with a large mass ([7 cm) in his left arm and
palpable axillary lymph nodes. Biopsy of the lesion
with an 18-gauge Tru-Cut needle and automatically
triggered biopsy gun was positive for melanoma and
BRAF V600E mutation. After the biopsy, the tumor
mass transformed to an open wound with constant
bleeding (Fig 1), necessitating prolonged hospitali-
zation. Fluorodeoxyglucose positron electron to-
mography (FDG-PET) examination showed uptake
in the primary site and left axilla, and suspicious
uptake in the left supraclavicular lymph nodes.
Axillary cytology via fine-needle aspiration was
positive for melanoma. The patient refused imme-
diate surgery, which would have involved disartic-
ulation amputation. Neoadjuvant treatment with
vemurafenib (Zelboraf, Hoffmann-La Roche), 960
mg orally twice daily, was instituted. A follow-up
visit 2 weeks later showed significant clinical
improvement. After 8 weeks of treatment, the
mass disappeared (Fig 2). There were no significant
side effects of vemurafenib treatment. A multidis-
ciplinary team decided to refer the patient to
surgery. Vemurafenib was continued until 2 days
before surgery. The patient underwent resection of
the recurrent skin lesion and axillary lymph node
dissection, all of which indicated complete patho-
logic response. Vemurafenib was not renewed after
surgery. The patient was followed every 3 months
by a physical examination and with FDG-PET every
6 months. At 18 months after surgery, he shows no
evidence of disease.
Neoadjuvant treatment for resectable/unresect-
able stage III melanoma remains an investigational
approach; there are neither large prospective ran-
domized trials nor recommended regimens ortimelines for a treatment frame, in that none of the
systemic therapies or radiotherapy for melanoma
were proven to be sufficiently active to support this
approach.1
Vemurafenib was approved by the Food and Drug
Administration in August 2011 for the treatment of
patients with unresectable or metastatic melanoma
with the BRAF V600E mutation based on a large
randomized study.2,3 The majority of the patients
(95%) had metastatic disease. Subgroup analysis of
overall survival indicated that the nonmetastatic
patients did not benefit from vemurafenib but a
significant benefit to this subgroup was shown with
regard to progression-free survival. It was not stated
whether these patients became operable or were
referred for surgical resection. There are no ongoing
trials evaluating the role of vemurafenib in the
neoadjuvant setting, and a literature review reveals
that there are only 2 other reports of vemurafenib in
the neoadjuvant setting.4,5
In the case presented, there was a pathologic
complete response; however, the role of vemurafe-
nib in locally advanced disease, whether in the
neoadjuvant or adjuvant setting, is yet to be deter-
mined. A major concern of this approach is the
possibility of gaining resistance to BRAF inhibition
and losing it as potential treatment in the metastatic
setting.
Fig 1. Nonuremic calciphylaxis in a patient treated with
teriparatide: livedoid erythema and retiform purpura on
the bilateral thighs.
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Nonuremic calciphylaxis in a patient with
rheumatoid arthritis and osteoporosis treated
with teriparatide
To the Editor: Calciphylaxis is a devastating condition
in which metastatic calcification of the microvascu-
lature results in thrombosis and ischemic necrosis of
target tissues.1-3 Calciphylaxis is well described
in patients with chronic kidney disease and second-
ary hyperparathyroidism, however the literature
describing it in the absence of these classic comor-
bidities is scant.
A 66-year-old woman presented with a 3-month
history of painful lower extremity nodules. Her
medical history included obesity, pulmonary
emboli, osteoporosis, and a 20-year history of well-
controlled rheumatoid arthritis. Medications
included leflunomide, prednisone (2 mg daily),
warfarin, and teriparatide [recombinant humanparathyroid hormone (1-34)], initiated 5 months
prior. Physical examination revealed a 10- 3 3-cm
indurated subcutaneous plaque with livedoid ery-
thema and retiform purpura on the bilateral thighs
and scattered indurated subcutaneous nodules on
the bilateral lower extremities (Fig 1). A lateral thigh
lesion was biopsied at an outside facility 2 months
prior, leaving a nonhealing ulcer despite appropriate
wound care. The biopsy specimen was consistent
with thrombotic vasculopathy; however, no addi-
tional workupwas performed. Von Kossa stains were
ordered and read by our pathologist, but no changes
of early calciphylaxis were seen. Laboratory studies
demonstrated normal renal function, parathyroid
hormone levels, and calcium-phosphate product.
Serum and urine protein electrophoresis, antineu-
trophil cytoplasmic antibodies, antinuclear anti-
bodies, and antiphospholipid antibodies were all
negative.
Because of the patient’s multiple risk factors,
calciphylaxis was suspected clinically. Warfarin and
teriparatide were discontinued and the patient was
placed on low-molecular-weight heparin. Given her
risk for poor wound healing, repeated biopsy was
deferred. Bone scintigraphy of the thighs showed no
abnormal uptake. Because of continued clinical
suspicion and further lesion progression, the patient
consented to repeated biopsy. Histopathology re-
vealed intramural calcium deposition in subcutane-
ous arterioles with intimal hyperplasia and ischemic
changes of the surrounding tissue consistent with
calciphylaxis (Fig 2). Treatment with intravenous
sodium thiosulfate therapy was initiated after
surgical consultants determined the patient was a
poor candidate for debridement. Unfortunately, her
lesions progressed over the next month causing
